1-<4-Amino-2-methoxy-phenoxy>-propan | 104338-87-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-<4-Amino-2-methoxy-phenoxy>-propan
• 英文别名: 3-Methoxy-4-propoxyaniline
• CAS: 104338-87-6
• 化学式: C₁₀H₁₅NO₂
• 分子量: 181.235
• InChiKey: PBSDUCLSAXJGLA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-<4-Amino-2-methoxy-phenoxy>-propan 、 2,4-diamino-5-methyl-5-deaza-6-bromomethylpteridine 生成 6-[(3-Methoxy-4-propoxy-phenylamino)-methyl]-5-methyl-pyrido[2,3-d]pyrimidine-2,4-diamine
  参考文献：
  名称：

  2,4-diamino-5-deazapteridine 衍生物的抗分枝杆菌活性及其对分枝杆菌二氢叶酸还原酶的影响。

  摘要：

  开发用于鸟分枝杆菌复合体 (MAC) 感染的新抗分枝杆菌药物对于同时感染人类免疫缺陷病毒的人来说尤其重要。本研究的目的是评估 2, 4-diamino-5-methyl-5-deazapteridines (DMDPs) 对 MAC 的体外活性，并评估它们对 MAC 二氢叶酸还原酶重组酶 (rDHFR) 的活性。最初评估了 77 种 DMDP 衍生物对一到三株 MAC（NJ168、NJ211 和/或 NJ3404）的体外活性。用 10 倍稀释的药物和比色法（Alamar Blue）微量稀释肉汤测定法测定 MIC。还确定了 MAC rDHFR 50% 抑制浓度与人 rDHFR 的抑制浓度。蝶啶部分第 5 位的取代基包括 -CH(3)、-CH(2)CH(3) 和 -CH(2)OCH(3) 基团。此外，不同的取代和未取代的芳基通过 -CH(2)NH、-CH(2)N(CH(3))、-CH(2)CH(2)

  DOI：

  10.1128/aac.44.10.2784-2793.2000
• 作为产物：
  描述：

  2-甲氧基-4-硝基-1-丙氧基-苯 在 镍 氢气 作用下， 生成 1-<4-Amino-2-methoxy-phenoxy>-propan
  参考文献：
  名称：

  363.血吸虫病的化学疗法。第四部分 4-氨基-2-甲氧基苯酚的一些醚

  摘要：

  DOI：

  10.1039/jr9610001863

文献信息

• [EN] AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS<br/>[FR] ANTAGONISTES DE RÉCEPTEUR-1 D'HORMONE DE MÉLANO-CONCENTRATION D'AZOLOTRIAZINONE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2010042682A1

  公开（公告）日：2010-04-15

  The present application provides compounds that are useful as MCHR1 antagonists, especially for the treatment of obesity, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I, wherein R1, is selected from the group consisting of monocyclic aryl or monocyclic heteroaryl; W is selected from the group consisting of a direct bond, -O-, and -N(R6)-; provided that if W is a direct bond, D is a cyclic amine that is attached to A via the nitrogen atom of the cyclic amine; D is selected from the group consisting of a direct bond, substituted or unsubstituted C1 to C4 alkyl, substituted or unsubstituted C3 to C7 cycloalkyl, cycloalkylalkyl, and 4- to 6-membered cyclic amines, provided that if D is a direct bond, R2a, R2b, and R2c must be selected from H, alkyl, or cycloalkyl; E and G are independently N or CH provided that both are not N; R1 is substituted or unsubstituted phenyl or substituted or unsubstituted monocyclic heteroaryl; R2a, R2b, and R2c are independently selected from the group consisting of hydrogen, halo, cyano, hydroxyl, -NR5R5a, -SO2R34, -CO2R35 -NR5CO2R21, -NR5COR21, substituted or unsubstituted C1 to C4 alkyl, substituted or unsubstituted C3 to C7 cycloalkyl, substituted or unsubstituted 4- to 6-membered cyclic amines wherein said cyclic amine is optionally substituted with -OH, carbonylamino, alkoxycarbonylamino, or at least one of R2a, R2b, and R2c is a prodrug moiety selected from amino acid esters or phosphoric acid esters wherein said amino acid ester has the formula -OC(O)CH(NH2)R31, wherein R31 is H or C1 to C4 alkyl; or any two of R2a, Rb, or R2c, may be taken together to form a ring; R3 and R3a are each independently selected from the group consisting of hydrogen, hydroxyl, lower alkoxy, halo, CN, substituted or unsubstituted C1 to C4 alkyl, perfluoroalkyl, substituted or unsubstituted C3 to C7 cycloalkyl, cycloalkoxy, amino, alkylamino, dialkylamino, and aminoalkyl, wherein R3 or R3a and D may optionally be taken together with the atoms to which they are attached to form a 5- to 7-membered ring; R5 and R5a are the same or different and are independently selected from the group consisting of hydrogen, substituted or unsubstituted lower alkyl, hydroxyalkyl, hydroxyalkylcycloalkyl, substituted or unsubstituted heterocycloalkyl, acyl, alkoxycarbonyl, carboxyalkyl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted cycloalkylalkyl, wherein the R5 and R5a groups and the N atom to which they are attached may form a ring; R21 and R31 are each H or C1 to C4 alkyl; R34 is alkyl; R35 is H or alkyl; and R6 is selected from the group consisting of H, C1 to C4 alkyl and C3 to C7 cycloalkyl.

  本申请提供了作为MCHR1拮抗剂有用的化合物，特别用于肥胖症的治疗，包括所有立体异构体、溶剂化合物、前药和根据式I的药学上可接受的形式，其中R1从单环芳基或单环杂芳基组成的群体中选择；W从直接键、-O-和-N(R6)-组成的群体中选择；条件是如果W是直接键，则D是通过环胺的氮原子连接到A的环胺；D从直接键、取代或未取代的C1到C4烷基、取代或未取代的C3到C7环烷基、环烷基烷基和4-到6-成员环胺组成的群体中选择，条件是如果D是直接键，则R2a、R2b和R2c必须从H、烷基或环烷基中选择；E和G独立地是N或CH，条件是两者都不是N；R1是取代或未取代的苯基或取代或未取代的单环杂芳基；R2a、R2b和R2c独立地从氢、卤素、氰基、羟基、-NR5R5a、-SO2R34、-CO2R35 -NR5CO2R21、-NR5COR21、取代或未取代的C1到C4烷基、取代或未取代的C3到C7环烷基、取代或未取代的4-到6-成员环胺中选择，其中所述环胺可以选择地取代为-OH、羰基氨基、烷氧羰基氨基，或R2a、R2b和R2c中的至少一个是选择自氨基酸酯或磷酸酯的前药基团，其中所述氨基酸酯具有式-OC(O)CH(NH2)R31，其中R31为H或C1到C4烷基；或R2a、Rb或R2c中的任意两个可以结合形成环；R3和R3a各自独立地从氢、羟基、较低烷氧基、卤素、CN、取代或未取代的C1到C4烷基、全氟烷基、取代或未取代的C3到C7环烷基、环烷氧基、氨基、烷基氨基、二烷基氨基和氨基烷基中选择，其中R3或R3a和D可以选择地结合形成5-到7-成员环；R5和R5a相同或不同，独立地从氢、取代或未取代的较低烷基、羟基烷基、羟基烷基环烷基、取代或未取代的杂环烷基、酰基、烷氧羰基、羧基烷基、取代或未取代的环烷基和取代或未取代的环烷基烷基中选择，其中R5和R5a基团和它们连接的N原子可以形成环；R21和R31各自为H或C1到C4烷基；R34为烷基；R35为H或烷基；R6从H、C1到C4烷基和C3到C7环烷基中选择。
• [EN] NOVEL KINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2014060113A1

  公开（公告）日：2014-04-24

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种具有公式（I）的新化合物，能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物在治疗多种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和激素相关疾病。
• [EN] PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2014060112A1

  公开（公告）日：2014-04-24

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及具有式（I）的新化合物，其能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物可用于治疗多种疾病。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和激素相关疾病。
• [EN] PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS<br/>[FR] DÉRIVÉS DE PIPÉRIDINE ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES MÉTABOLIQUES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012001107A1

  公开（公告）日：2012-01-05

  The invention relates to new piperidine derivatives of the formula (I) to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  本发明涉及一种新的哌啶衍生物，其化学式为（I），以及它们作为药物的用途，它们的治疗用途的方法以及包含它们的制药组合物。
• NOVEL KINASE INHIBITORS
  申请人：ORIGENIS GMBH

  公开号：US20150259340A1

  公开（公告）日：2015-09-17

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及式（I）的新型化合物，能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物可用于治疗各种疾病。这些疾病包括自身免疫性疾病、炎症性疾病、骨病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。